Table 2

Prognostic markers, clinical variables, and cluster groups in univariate analysis of disease-specific survival

Marker or Factor (cutoff)*No. of interpretable casesSignificance (P value)
1PR (score 0 vs. 1, 2, and 3)357P = 0.007, positive factor
2ER (score 0 vs. 1, 2, and 3)324P = 0.005, positive factor
3HER2 (score 0 and 1 vs. 3)337P = 0.03, negative factor
4p53 (score 0 vs. 1 and 3)309P = 0.001, negative factor
5Her3 (scores 0 and 1 vs. 2 and 3)278P = 0.01, negative factor
6Cox2 (scores 0 and 1 vs. 2 and 3)356P = 0.003, negative factor
7NSE (score 0 vs. 1, 2, and 3)335P = 0.04, positive factor
8Relaxin (score 0 vs. 1, 2, and 3)361P = 0.02, positive factor
9Ki67 (score 0 vs. 1, 2, and 3)319P = 0.02, negative factor
10CA IX (score 0 vs. 1 and 2)322P = 0.05, negative factor
11TIP1(scores 0, 1, and 2 vs. 3)272P = 0.01, negative factor
12PTEN(scores 0 vs. 1, 2, and 3)344P = 0.003, positive factor
13IGFBP2 (scores 0 and 1 vs. 2 and 3)301P = 0.04, negative factor
14IGFBP5(scores 0 and 1 vs. 2 and 3)301P = 0.05, negative factor
15Mast cell (CD117) (score 0 vs. 1)346P = 0.003, positive factor
16CD10 (scores 0, 1, and 2 vs. 3)300P = 0.008, negative factor
17YB1 (scores 0, 1, and 2 vs. 3)305P = 0.01, negative factor
18CD68 (scores 0 and 1 vs. 2 and 3)331NS (P = 0.074)
19HSP27(score 0 vs. 1, 2, and 3)300NS (P = 0.14)
20p63 (score 0 vs. 1, 2, and 3)376NS (P = 0.2)
21CK5/6 (score 0 vs. 1, 2, and 3)350NS (P = 0.06)
22Lymph node metastasis392P < 0.0001, negative factor
23Tumor size366P < 0.0001, negative factor
24Tumor grade438NS (P = 0.08), negative factor
25Cluster groups based on 21 markers281NS (P = 0.15)
26Cluster groups based on 20 markers277P = 0.0025
27Cluster groups based on 19 markers267P = 0.0003 (P = 0.0014)§
28Cluster groups based on 18 markers272P = 0.0012
29Cluster groups based on 17 markers273NS (P = 0.18)
30Cluster groups based on 11 markers294P < 0.0001 (P = 0.0001)§
  • Abbreviations: NS, nonsignificant (P > 0.05); NSE, neuron-specific enolase.

  • * Survival analysis was done on binary data using the cutoff points identified.

  • Reached significance in node-negative subset of patients only; P < 0.2 for all patients.

  • Cluster group 1 versus 2 and 3.

  • § Cluster group 1 versus 2 versus 3.